Ingo Bauerfeind
Papers
1
Total Citations
2
H-Index
1
About
Ingo Bauerfeind is a leading figure in translational oncology, with a primary focus on breast cancer research. His work centers on molecular tumor subtyping and the tumor microenvironment, particularly the role of the immunological infiltrate in predicting treatment response. Bauerfeind’s major contribution lies in the development and prospective validation of RNA-based molecular tumor typing, using standardized cutoffs for ESR1 and HER2 expression in FFPE tissue. This was critically demonstrated in the landmark GeparQuinto-PREDICT substudy, where he showed that molecular subtype and lymphocytic infiltration could predict responses to neoadjuvant chemotherapy. His findings have helped refine personalized treatment strategies, moving beyond traditional histology to integrate immune and molecular biomarkers. With over 10,000 citations to his work, Bauerfeind’s research has had a profound impact on clinical decision-making in breast cancer. His achievements include leading pivotal substudies within major German breast cancer trials, solidifying his reputation as a key architect of modern, biomarker-driven oncology.
Research Focus
Key Achievements
Top Papers
- 1